Portfoliotracker

InSilico Medicine Cayman TopCo

3696.HK · HKSE · Healthcare Biotechnology 34/100 E

34,16 HKD
▼ −1,40 (−3,94 %)
Closed delayed by 15 min
Price as of 17. 11. 09:08, fetched 17. 11. 15:18
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score34 / 100 Market cap20,1 mld. HKD P/E– Forward P/E19,9 P/S148,4 P/B4,6 EV/EBITDA– Dividend yield– FCF yield– EPS-34,26 HKD Net margin-220,3 % Return on equity– Beta– Debt / equity0,04
52-week range 29,98 to 80,90
3-month average volume14,1 M

We do not have financial statements yet

The company reports in USD, while the price is quoted in HKD. We do not convert statements between currencies yet, because the multiples (P/E, P/S and others) would come out wrong, so we do not show them here. You can see the price and its history above.

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. InSilico Medicine Cayman TopCo has a strategic collaboration agreement with Takeda to use its proprietary Pharma.AI, to advance drug candidates; and collaboration with Servier for researching and developing programs for oncology. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.

Employees
333
Country
Hong Kong
Data since
30. 12. 2025

Explore further

Similar companies 2513.HK0100.HK6082.HK2228.HK

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account